Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Clinical profile and drug therapy of outpatients with arterial hypertension

https://doi.org/10.20996/1819-6446-2020-04-04

Full Text:

Abstract

Aim. To study clinical profile and antihypertensive treatment features in outpatients observed in ambulatory facilities.

Material and methods. 140 arterial hypertension (AH) outpatients were examined, questioning and anthropometry were performed. Blood pressure (BP) was measured on both hands, then twice on the hand with larger value, the medium value was calculated. Tests results were obtained from outpatient cards.

Results. The sampling included 100 (71.4%) females and 40 (28.6%) males. Median of systolic BP at first measurement was 140.0 mm Hg (130.0;150.0), mean value of three BP measurements was 138.0 mm Hg (127.0;150.0) (p<0.001); median diastolic BP at first measurement was 83.0 mm Hg (80.0;90.0), mean BP value was 82.0 mm Hg (78.0;88.0) (p<0.001). Grade 1 AH was identified in 11.4% of patients, Grade 2 – in 35.7%, Grade 3 in 52.9%. No target organ damage was found in 26.4% of AH patients, asymptomatic target organ damage was diagnosed in 26.4%, and 61.4% had associated clinical conditions. Cardiovascular event risk was assessed as moderate in 13.6%, high – in 24.3% and very high – in 62.1% of patients. Every third patient had myocardial hypertrophy signs; Cornell index was detected more often than Sokolov-Layon index (p=0.006). Chronic kidney disease was diagnosed in 65.1% of patients: 44.0% of them had stage C2, 13.8% – stage C3A, 6.5% – stage C3B, and 1.8% – stage C4. 97.9% of AH patients received antihypertensive treatment. Daily medication consumption was reported by 127 people, and 10 patients reported taking medication as needed. Monotherapy was prescribed in 14.3% of patients; combined treatment was performed in 83.6% people. BP target value was achieved in 59 patients (42.1%) at first measurement results and in 71 (50.7%) ones at calculated mean value (p=0.002). Indications for statin use were identified in 86.4% of patients. Statins were administered in 56.2% patients having indications and in 21.1% of subjects without indications (p=0.006). Indications for antiplatelet therapy use were identified in 56.4% of patients. Antiplatelet treatment was administered in 58.2% of patients with indications and in 23.0% of subjects without indications (p<0.001).

Conclusion. Glomerular filtration rate and left ventricular myocardial hypertrophy amplitude criteria calculation allow to diagnose subclinical target organ damage in outpatients at physician visit without additional costs. Compliance with the current antihypertensive therapy guidelines allows to achieve target BP in current practice. Compliance with the BP measuring rules allows to adequately assess the effectiveness of antihypertensive therapy. A significant proportion of AH outpatients have a very high cardiovascular risk, which requires lipid-lowering and antiplatelet therapy.

About the Authors

N. V. Izmozherova
Urals State Medical University
Russian Federation

Nadezhda V. Izmozherova– MD, PhD, Associate Professor, Head of Chair of Pharmacology and Clinical Pharmacology

Repina ul. 3, Yekaterinburg, 620028 



A. A. Popov
Urals State Medical University
Russian Federation

Artem A. Popov – MD, PhD, Associate Professor, Chair of Head of Hospital Therapy and Emergency Medical Care

Repina ul. 3, Yekaterinburg, 620028 



V. M. Bakhtin
Urals State Medical University
Russian Federation

Victor M. Bakhtin – Postgraduate Student, Chair of Pharmacology and Clinical Pharmacology

Repina ul. 3, Yekaterinburg, 620028 



M. A. Shambatov
Urals State Medical University
Russian Federation

Muraz A. Shambatov – Student

Repina ul. 3, Yekaterinburg, 620028 



References

1. Oganov R.G., Timofeeva T.N., Koltunov I.E., et al. Arterial hypertension epidemiology in Russia; the results of 2003-2010 federal monitoring. Cardiovascular Therapy and Prevention. 2011;10(1):9-13 (In Russ.)

2. Boytsov S.A., Balanova Y.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-2014-4-4-14.

3. Badin Y.V., Fomin I.V., Belenkov Y.N., et al. EPOCHA-AH 1998-2017. Dynamics of prevalence, awareness of arterial hypertension, treatment coverage, and effective control of blood pressure in the European part of the Russian Federation. Kardiologiia. 2019;59(1S):34-42 (In Russ.) DOI:10.18087/cardio.2445.

4. Nedogoda S.V., Sabanov A.V. Target blood pressure achievement in arterial hypertension patients on the anti-hypertensive therapy background in real clinic practice. Russian Journal of Cardiology. 2018;23(11):100-9 (In Russ.) DOI:10.15829/1560-4071-2018-11-100-109.

5. Andreeva O.Y., Melekhov A.V., Gendlin G.E., Nikitin I.G. Arterial hypertension patient treatment in real ambulatory practice. Russian Medical Journal. 2018;24(1):4-8 (In Russ.) DOI:10.18821/0869-2106-2018-24-1-4-8.

6. Popugaev A.I., Rybakov D.A, Banshchikov G.T., et al. Arterial hypertension registry in Vologda Region. Cardiovascular Therapy and Prevention. 2007; 6(2):23-7 (In Russ,)

7. Leonova M.V., Shteinberg L.L., Belousov Y.B., et al. Arterial hypertension pharmacoepidemiological study “PIFAGOR IV” results: doctors commitment. Russian Journal of Cardiology. 2015;1(117):59- 66 (In Russ.) DOI:10.15829/1560-4071-2015-1-59-66.

8. Boytsov S.A., Luk’yanov M.M., Yakushin S.S., et al. Cardiovascular diseases registry (RECVAZA): diagnostics, concomitant cardiovascular pathology, comorbidities and treatment in the real outpatientpolyclinic practice. Cardiovascular Therapy and Prevention. 2014;13(6):44-50. Russian. DOI:10.15829/1728-8800-2014-6-44-50.

9. WHO Expert Committee. Hypertension control, WHO Tech Rep Ser no. 862. Geneva: World Health Organization; 1996.

10. Boytsov S.A., Pogosova N.V., Bubnova M.G., et al. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology. 2017;23(6):7-122 (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122.

11. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. DOI:10.1016/S0140-6736(09)60503-1.

12. Muromtseva G.A., Vilkov V.G., Konstantinov V.V., et al. The prevalence of electrocardiographic abnormalities in the Russian population in the early 21st century (the ESSE-RF study). Russian Journal of Cardiology. 2018;23(12):7-17 (In Russ.) DOI:10.15829/1560-4071-2018-12-7-17.

13. van Kleef M.E.A.M., Visseren F.L.J., Vernooij J.W.P., et al. on behalf of the SMART-study group. Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease. J Hypertens. 2018;36(1):1865-73. doi:10.1097/HJH.0000000000001785.

14. Oshchepkova E.V., DolgushevaIu.A., Zhernakova I.V., et al. The prevalence of renal dysfunction in arterial hypertension (in the framework of the ESSE-RF study). Systemic Hypertension. 2015;12(3):19- 24 (In Russ.)

15. Chazova I.E., Zhernakova Y.V. on behalf of experts. Arterial hypertension diagnostics and treatment. Clinical recommendations. Systemic Hypertension. 2019;1:6-31 (In Russ.) DOI:10.26442/2075082X.2019.1.190179.

16. Komarova O.A., Ataullakhanova D.M., Klimenko V.S., et al. Comparative evaluation of criteria for informational detection of left ventricular myocardial hypertrophy in patients with arterial hypertension. Russian Journal of Cardiology. 2007;1(63)32-35 (In Russ.)

17. Shuck O., Teplan V., Maly J., et al. The relationship between estimated GFR based on the CKD-EPI formula and renal inulin clearance in potential kidney donors. Clinical Hephrology. 2014:82(6):353- 7. DOI:10.5414/CN108341.


For citation:


Izmozherova N.V., Popov A.A., Bakhtin V.M., Shambatov M.A. Clinical profile and drug therapy of outpatients with arterial hypertension. Rational Pharmacotherapy in Cardiology. 2020;16(2):206-212. (In Russ.) https://doi.org/10.20996/1819-6446-2020-04-04

Views: 185


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)